{"entity":{"id":"nct06127407","kind":"trial","name":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen","aka":["CHONQUER"],"tldr":"A phase 3 trial of Ivosidenib in sarcomas, run by Servier Bio-Innovation LLC, now recruiting.","summary":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen is a phase 3 interventional study registered as NCT06127407 by Servier Bio-Innovation LLC, with 136 participants planned, started 2024-07-09 and due to reach its primary completion in 2028-02-01. Interventions recorded: Ivosidenib 500mg and Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06127407","url":"https://clinicaltrials.gov/study/NCT06127407"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sarcoma","chondrosarcoma"],"sections":[],"technologies":["epigenetic-drugs","idh-inhibitors","kinase-inhibitors"],"targets":[],"drugs":["ivosidenib"],"companies":["servier"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06127407","phase":"3","setting":"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen","sponsor":"Servier Bio-Innovation LLC","started":"2024-07-09","startedType":"actual","enrolled":136,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06127407/","neighbours":{"cancer":[{"id":"chondrosarcoma","kind":"cancer","name":"Chondrosarcoma","route":"/cancers/chondrosarcoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"technology":[{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"},{"id":"idh-inhibitors","kind":"technology","name":"IDH inhibitors","route":"/technologies/idh-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"ivosidenib","kind":"drug","name":"Ivosidenib","route":"/drugs/ivosidenib/"}],"company":[{"id":"servier","kind":"company","name":"Servier","route":"/companies/servier/"}]}}